|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.||CEO & Member of Management Board||705,82k||N/D||1970|
|Mr. Pierre Kemula B.Sc.||MD, CFO & Member of Management Board||686,61k||N/D||1974|
|Ms. Mariola Fotin-Mleczek||CTO & Member of Management Board||549,09k||N/D||1968|
|Dr. Igor Splawski M.Sc., Ph.D.||Chief Scientific Officer & Member of Management Board||462,81k||N/D||1969|
|Dr. Antony Blanc||MD, Chief Bus. Officer & Chief Commercial Officer||418,57k||N/D||1969|
|Dr. Klaus Edvardsen M.D., Ph.D.||Chief Devel. Officer||N/D||N/D||N/D|
|Mr. Malte Greune Ph.D.||COO & Member of Management Board||N/D||N/D||N/D|
|Dr. Sarah Fakih||VP Corp. Communications & Investor Relations||N/D||N/D||N/D|
|Mr. Thorsten Schuller||Head of Corp. Communications||N/D||N/D||N/D|
|Slavica Stevanovic-Heck||Head of HR||N/D||N/D||N/D|
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.
L'ISS Governance QualityScore di CureVac N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.